BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 36253752)

  • 1. CD4 and FOXP3 as predictive markers for the recurrence of T3/T4a stage II colorectal cancer: applying a novel discrete Bayes decision rule.
    Nakagami Y; Hazama S; Suzuki N; Yoshida S; Tomochika S; Matsui H; Shindo Y; Tokumitsu Y; Matsukuma S; Watanabe Y; Iida M; Tsunedomi R; Takeda S; Fujita T; Kawakami Y; Ogihara H; Hamamoto Y; Ioka T; Tanabe T; Ueno T; Nagano H
    BMC Cancer; 2022 Oct; 22(1):1071. PubMed ID: 36253752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intratumoural-infiltrating CD4 + and FOXP3 + T cells as strong positive predictive markers for the prognosis of resectable colorectal cancer.
    Kuwahara T; Hazama S; Suzuki N; Yoshida S; Tomochika S; Nakagami Y; Matsui H; Shindo Y; Kanekiyo S; Tokumitsu Y; Iida M; Tsunedomi R; Takeda S; Yoshino S; Okayama N; Suehiro Y; Yamasaki T; Fujita T; Kawakami Y; Ueno T; Nagano H
    Br J Cancer; 2019 Oct; 121(8):659-665. PubMed ID: 31488881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Immune-Related Factors as Prognostic Markers for Resectable Colorectal Cancer].
    Tomochika S; Kuwahara T; Suzuki N; Hazama S; Nagano H
    Gan To Kagaku Ryoho; 2021 Mar; 48(3):325-330. PubMed ID: 33790150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SPARC, FOXP3, CD8 and CD45 correlation with disease recurrence and long-term disease-free survival in colorectal cancer.
    Chew A; Salama P; Robbshaw A; Klopcic B; Zeps N; Platell C; Lawrance IC
    PLoS One; 2011; 6(7):e22047. PubMed ID: 21818290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiplex analysis of intratumoural immune infiltrate and prognosis in patients with stage II-III colorectal cancer from the SCOT and QUASAR 2 trials: a retrospective analysis.
    Frei AL; McGuigan A; Sinha RRAK; Jabbar F; Gneo L; Tomasevic T; Harkin A; Iveson T; Saunders MP; Oien KA; Maka N; Pezzella F; Campo L; Browne M; Glaire M; Kildal W; Danielsen HE; Hay J; Edwards J; Sansom O; Kelly C; Tomlinson I; Kerr R; Kerr D; Domingo E; ; Church DN; Koelzer VH
    Lancet Oncol; 2024 Feb; 25(2):198-211. PubMed ID: 38301689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FOXP3-based immune risk model for recurrence prediction in small-cell lung cancer at stages I-III.
    Jiang M; Wu C; Zhang L; Sun C; Wang H; Xu Y; Sun H; Zhu J; Zhao W; Fang Q; Yu J; Chen P; Wu S; Zheng Z; He Y; Zhou C
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34006632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased number of forkhead box P3+ tumor-infiltrating lymphocytes correlates with high preoperative albumin level and better survival in patients with stage II or III colorectal cancer.
    Wang DL; Liu YY; Gu YL; Qin Y; Ji HF; Wu LH; Qi N; Su D; Huang SH; Zhang YQ
    Tumour Biol; 2015 Jul; 36(7):5407-14. PubMed ID: 25697896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of sidedness of colorectal cancer on tumor immunity.
    Takasu C; Nishi M; Yoshikawa K; Tokunaga T; Kashihara H; Yoshimoto T; Shimada M
    PLoS One; 2020; 15(10):e0240408. PubMed ID: 33045001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic value of FOXP3+ T regulatory cells in colorectal cancer.
    Vlad C; Kubelac P; Fetica B; Vlad D; Irimie A; Achimas-Cadariu P
    J BUON; 2015; 20(1):114-9. PubMed ID: 25778305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated serum carcinoembryonic antigen level after curative surgery is a prognostic biomarker of stage II-III colorectal cancer.
    Sonoda H; Yamada T; Matsuda A; Ohta R; Shinji S; Yokoyama Y; Takahashi G; Iwai T; Takeda K; Ueda K; Kuriyama S; Miyasaka T; Yoshida H
    Eur J Surg Oncol; 2021 Nov; 47(11):2880-2887. PubMed ID: 34103245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High intratumoral FOXP3⁺ T regulatory cell (Tregs) density is an independent good prognosticator in nodal negative colorectal cancer.
    Hanke T; Melling N; Simon R; Sauter G; Bokemeyer C; Lebok P; Terracciano LM; Izbicki JR; Marx AH
    Int J Clin Exp Pathol; 2015; 8(7):8227-35. PubMed ID: 26339391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer.
    Gao S; Tibiche C; Zou J; Zaman N; Trifiro M; O'Connor-McCourt M; Wang E
    JAMA Oncol; 2016 Jan; 2(1):37-45. PubMed ID: 26502222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic Analysis of Predictive Biomarkers for Recurrence in Colorectal Cancer Patients Treated with Curative Surgery.
    Mori K; Toiyama Y; Saigusa S; Fujikawa H; Hiro J; Kobayashi M; Ohi M; Araki T; Inoue Y; Tanaka K; Mohri Y; Kusunoki M
    Dig Dis Sci; 2015 Aug; 60(8):2477-87. PubMed ID: 25840921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stratification of chemotherapy-treated stage III colorectal cancer patients using multiplexed imaging and single-cell analysis of T-cell populations.
    Stachtea X; Loughrey MB; Salvucci M; Lindner AU; Cho S; McDonough E; Sood A; Graf J; Santamaria-Pang A; Corwin A; Laurent-Puig P; Dasgupta S; Shia J; Owens JR; Abate S; Van Schaeybroeck S; Lawler M; Prehn JHM; Ginty F; Longley DB
    Mod Pathol; 2022 Apr; 35(4):564-576. PubMed ID: 34732839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transcriptional signatures for coupled predictions of stage II and III colorectal cancer metastasis and fluorouracil-based adjuvant chemotherapy benefit.
    Song K; Guo Y; Wang X; Cai H; Zheng W; Li N; Song X; Ao L; Guo Z; Zhao W
    FASEB J; 2019 Jan; 33(1):151-162. PubMed ID: 29957060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LGR5 and CD133 as prognostic and predictive markers for fluoropyrimidine-based adjuvant chemotherapy in colorectal cancer.
    Stanisavljević L; Myklebust MP; Leh S; Dahl O
    Acta Oncol; 2016 Dec; 55(12):1425-1433. PubMed ID: 27435662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of multiple molecular markers for patients with stage II colorectal cancer undergoing curative resection.
    Uen YH; Lin SR; Wu DC; Su YC; Wu JY; Cheng TL; Chi CW; Wang JY
    Ann Surg; 2007 Dec; 246(6):1040-6. PubMed ID: 18043108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Colorectal obstruction is a potential prognostic factor for stage II colorectal cancer.
    Okuda Y; Shimura T; Yamada T; Hirata Y; Yamaguchi R; Sakamoto E; Kataoka H
    Int J Clin Oncol; 2018 Dec; 23(6):1101-1111. PubMed ID: 29948240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer.
    Kim ST; Jeong H; Woo OH; Seo JH; Kim A; Lee ES; Shin SW; Kim YH; Kim JS; Park KH
    Am J Clin Oncol; 2013 Jun; 36(3):224-31. PubMed ID: 22495453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sidedness Matters: Surrogate Biomarkers Prognosticate Colorectal Cancer upon Anatomic Location.
    Ben-Aharon I; Goshen-Lago T; Sternschuss M; Morgenstern S; Geva R; Beny A; Dror Y; Steiner M; Hubert A; Idelevich E; Shulman K; Mishaeli M; Man S; Liebermann N; Soussan-Gutman L; Brenner B
    Oncologist; 2019 Aug; 24(8):e696-e701. PubMed ID: 30755502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.